Andre M. Murad

Belo Horizonte, MG 30130090, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report.

Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report.

Journal: Journal of medical case reports

Published: June 26, 2023

Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of gastric cancer.

Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of gastric cancer.

Journal: Ecancermedicalscience

Published: August 02, 2020

Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer.

Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer.

Journal: Ecancermedicalscience

Published: July 11, 2020

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 29, 2020

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: April 26, 2017

BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES.

BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES.

Journal: Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery

Published: January 25, 2016

GUIDELINE FOR THE MANAGEMENT OF BILE DUCT CANCERS BY THE BRAZILIAN GASTROINTESTINAL TUMOR GROUP.

GUIDELINE FOR THE MANAGEMENT OF BILE DUCT CANCERS BY THE BRAZILIAN GASTROINTESTINAL TUMOR GROUP.

Journal: Arquivos de gastroenterologia

Published: June 18, 2015

Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study.

Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study.

Journal: Journal of gastrointestinal oncology

Published: November 04, 2013

Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.

Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 19, 2013

Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer.

Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer.

Journal: American journal of clinical oncology

Published: April 26, 2003

Showing 1-10 of 10

Last Updated: 09/26/2026